ANKUR
DRUGS AND PHARMA LTD

14th May, 2012

To
National Stock Exchange of India Limited,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East)
Mumbai – 400 051

Stock Code: ANKURDRUGS

Sub: Un-audited Result for the Quarter ended March 31, 2012

Dear Sir,

Pursuant to Clause 41 of the Listing Agreement, please find enclosed herewith the Un-audited Financial Results for the Quarter ended March 31, 2012.

You are requested to kindly take note of the same.

Thanking You,

Yours Faithfully
For ANKUR DRUGS AND PHARMA LIMITED

AUTHORISED SIGNATORY

Encl: As Above

ANKUR DRUGS AND PHARMA LIMITED

Registered Office: C-306, Crystal Plaza, Andheri Link Road, Andheri (West), Mumbai- 400 053

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST MARCH, 2012

(INR in lacs)

Sr. No.	Particulars	Quarter ended on 31.03.2012 (Un-audited)	Quarter ended on 31.03.2011 (Un-audited)	Year ended on 31.03.2012 (Un-audited)	Year ended on 31.03.2011 (Un-audited)	Year ended on 31.03.2011 (Audited)
1.	a) Net Sales/Income from Operations (Net of Excise Duty)	3,777.83	12,123.92	15,270.26	82,399.73	82,399.74
	b) Other Operating Income	15.90	19.12	37.89	81.02	55.93
	Total Income from Operations (Net)	3,793.73	12,143.04	15,308.15	82,480.75	82,455.67
2.	**EXPENSES**					
	a) Cost of materials consumed/sold	3,037.46	6,203.51	9,357.78	57,175.31	57,679.92
	b) Purchases of stock in trade	-	-	35.23	-	-
	c) Changes in inventories of finished goods, work in progress and stock in trade	137.36	4,630.45	1,868.45	3,961.96	3,961.96
	d) Employee benefit expenses	653.68	839.09	2,891.07	2,972.92	2,865.41
	e) Depreciation and amortisation expenses	1,660.62	2,186.38	6,603.10	6,080.60	6,079.70
	f) Other expenses	1,110.37	1,174.27	3,966.20	5,020.60	4,643.52
	Total Expenses	6,599.49	15,033.70	24,721.83	75,211.39	75,230.51
3.	**PROFIT/(LOSS) FROM OPERATIONS BEFORE OTHER INCOME, INTEREST AND EXCEPTIONAL ITEMS (1-2)**	(2,805.76)	(2,890.66)	(9,413.68)	7,269.36	7,225.16
4.	Other Income	1.18	-	6.61	-	122.33
5.	**PROFIT/(LOSS) FROM ORDINARY ACTIVIES BEFORE FINANCE COST AND EXCEPTIONAL ITEMS (3+4)**	(2,804.58)	(2,890.66)	(9,407.07)	7,269.36	7,347.49
6.	**FINANCE COST**					
	a) Interest and other financial charges (net of reversal of interest for previous year)	1,489.43	3,218.08	4,540.58	10,821.83	10,926.97
	b) Provision for exchange difference on FCCBs	1,613.97	(157.47)	1,613.97	(157.47)	-
	c) Provision for premium on redemption of FCCBs	582.79	364.80	1,131.65	1,044.68	1,097.07
7.	**PROFIT/(LOSS) FROM ORDINARY ACTIVITIES AFTER FINANCE COSTS BUT BEFORE EXEPTIONAL ITEMS (5-6)**	(6,490.77)	(6,316.07)	(16,693.27)	(4,439.68)	(4,676.55)
8.	**EXCEPTIONAL COST**					
	a) Dimniution in value of investments	-	55.38	-	(20.63)	-
	b) Expired Inventories/Goods written off	2,336.89	-	2,336.89	-	-
9.	**PROFIT/(LOSS) FROM ORDINARY ACTIVITIES BEFORE TAX (7+8)**	(8,827.66)	(6,371.45)	(19,030.16)	(4,419.05)	(4,676.55)
10.	**TAX EXPENSE**					
	a) Income Tax (including for earlier years)	278.99	(390.00)	278.99	-	141.07
	b) Deferred Tax	2,848.25	2,093.90	2,848.25	2,093.90	2,063.18
11.	**NET PROFIT/LOSS FROM ORDINARY ACTIVITIES AFTER TAX (9-10)**	(11,954.90)	(8,075.35)	(22,157.40)	(6,512.95)	(6,880.80)
12.	**Extra Ordinary item (net of tax expense)**	-	-	-	-	-
13.	**NET PROFIT/(LOSS) FOR THE PERIOD (11-12)**	(11,954.90)	(8,075.35)	(22,157.40)	(6,512.95)	(6,880.80)
14	Share of Profit/(loss) of associates*	-	-	-	-	-
15	Minority Interest *	-	-	-	-	-
16	**NET PROFIT/(LOSS)AFTER TAXES, MINORITY INTEREST AND SHARED OF PROFIT/(LOSS) OF ASSOCIATES (13+14+15)**	(11,954.90)	(8,075.35)	(22,157.40)	(6,512.95)	(6,880.80)
17	Paid-up Equity Share Capital (of Rs.10/- each)	1,934.16	1,934.16	1,934.16	1,934.16	1,934.16

18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	26,913.23
19.i.	**Earning per share (before extraordinary items (Rs.)** (on face value of Rs.10/- each)- (not annualised):					
	-Basic	**(61.81)**	(41.75)	**(114.56)**	(33.67)	(35.58)
	-Diluted	**(21.55)**	(32.43)	**(39.94)**	26.15	(23.20)
19.ii.	**Earning per share (after extraordinary items (Rs.)** (on face value of Rs.10/- each)- (not annualised)					
	-Basic	**(61.81)**	(41.75)	**(114.56)**	(33.67)	(35.58)
	-Diluted	**(21.55)**	(32.43)	**(39.94)**	26.15	(23.20)
PART II						
A	**PARTICULARS OF SHAREHOLDING**					
1	Public Shareholding					
	-Number of Shares	16120865	14,601,709	16120865	14,601,709	14,601,709
	-Percentage of Shareholding (%)	83.35	75.49	83.35	75.49	75.49
2	**Promoters and promoter group shareholding****					
	a) Pledged/Encumbered					
	-Number of Shares	2252000	3773000	2252000	3773000	3773000
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	69.92	79.60	69.92	79.60	79.60
	-Percentage of shares (as a % of the total share capital of the Company)	11.64	19.51	11.64	19.51	19.51
	b) Non-encumbered					
	-Number of Shares	968725	966881	968725	966881	966881
	-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	30.08	20.40	30.08	20.40	20.40
	-Percentage of shares (as a % of the total share capital of the company)	5.01	5.00	5.01	5.00	5.00

	Particulars	3 months ended 31/03/2012
B	**INVESTOR COMPLAINTS**	
	Pending at the beginning of the quarter	0
	Received during the quarter	1
	Disposed of during the quarter	1
	Remaining unresolved at the end of the quarter	NIL

NOTES:

1. The above results were reviewed by the Audit Committee and approved by the Board of Directors of the company in their meeting held on 14th May, 2012
2. As Central Bank of India has advised to the company that Mr. Mr. B. K. Singal, proposed Nominee Director on the board of the Company has been transferred from his present posting and therefore the name of another representative of Central Bank of India would be intimated to company shortly. In view of above, appointment of Mr. B.K. Singal, as Nominee Director of Central Bank of India has been deferred by the Board.
3. The Board passed the resolution to Increase Authorized Share Capital of the company from Rs.156 Crores to Rs.185.Crores in pursuance of Section 16, 31, 94 of the Companies Act, 1956 and the subsequent Alteration of Memorandum and Articles of Association subject to approval of the shareholders
4. As per the terms and conditions of Corporate Debt Restructuring Scheme approved by the CDR EG, Unsecured loans of Rs.144.27 crores from the promoters, their relatives, friends and associates are to be converted into Equity Shares. Since the said Unsecured Loans are already with the company and on the basis of confirmation received from the promoter group to treat the said Unsecured Loans as share application money for equity shares with effect from reference date of the CDR i.e. 30th August, 2011, the board passed the resolution to treat the same as application money for equity shares so as to implement the Corporate Debt Restructuring Scheme subject to approval of the shareholders
5. The board of directors has passed the resolution to convert aforesaid Rs.144.27 Crores into Equity Shares at a price of Rs.46/- (including share premium) per equity share of Rs.10/- each as an additional capital in terms of CDR EG, on preferential allotment basis to the promoter group subject to approval of the shareholders.
6. The Board of directors approved the proposal for conducting Postal Ballot for the items 3,4 and 5 above and the Calender of Events thereof. The Board also appointed Mr. Sudhir Kamath, Practising Company Secretary as the Scrutinizer for the same
7. As the company operates in a single business segment viz: "Pharmaceuticals Formulations", in the context of Accounting Standard 17 disclosure of segment information is not applicable

8 **Statement of Assets & Liabilities:**

	Particulars	Year ended 31.03.12 (Un-audited)	Year ended 31.03.11 (Audited)
A	**EQUITY AND LIABILITIES**		
1	**Shareholders' funds**		
	a) Share Capital	1,934.16	1,934.16
	b) Reserves & Surplus	20,532.08	26,913.23
	c) Money received under share warrant	-	-
	Sub-total Shareholders' funds	**22,466.24**	**28,847.39**
2	**Application money pending allotment**		
	a) 0.001% OCCRPS Application money	-	-
	b) Share Application Money	13,219.79	-
		14,426.98	-
3	**Non-current liabilities**		
	a) Long term borrowings	66,020.66	52,310.00
	b) Deffered tax liabilities (net)	8,539.41	5,691.16
	c) Long term provisions	-	1,936.95
	Sub-total Non current liabilities	**74,560.07**	**59,938.11**
4	**Current Liabilities**		
	a) Short term borrowings	35,147.89	67,163.38
	b) Trade payables	10,281.76	18,009.77
	c) Other current liabilities	3,019.16	2,121.47
	d) Short term provisions	2,822.33	3,421.43
	Sub-total current liabilities	**51,271.14**	**90,716.05**
	TOTAL EQUITY AND LIABILITIES	**175,944.22**	**179,501.55**
B	**ASSETS**		
1	**Non-current Assets**		
	a) Fixed Assets	144,546.44	150,495.37
	b) Non current Investments	10.06	10.06
	c) Other non-current assets (Misc. Expenditure not w/off)	4,353.16	4,836.84
	Sub-total non-current assets	**148,909.66**	**155,342.27**
2	**Current Assets**		
	a) Inventories	6,740.76	16,535.73
	b) Trade receivables	3,281.37	3,803.48
	c) Cash and Cash equivalents	230.54	366.65
	d) Short term loans and advances	67.02	91.61
	e) Other current assets	938.62	3,361.81
	Sub-total current assets	**11,258.31**	**24,159.28**
3	**Profit & Loss Account**	**15,776.25**	-
	TOTAL ASSETS	**175,944.22**	**179,501.55**

For ANKUR DRUGS AND PHARMA LIMITED

Place : Mumbai.
Dated: 14th May, 2012

PURNANDU JAIN
Chairman and Managing Director